Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Current Liabilities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Total Current Liabilities for 16 consecutive years, with $347.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 270.56% year-over-year to $347.4 million, compared with a TTM value of $347.4 million through Dec 2025, up 270.56%, and an annual FY2025 reading of $195.5 million, up 89.48% over the prior year.
  • Total Current Liabilities was $347.4 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $195.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $347.4 million in Q4 2025 and bottomed at $63.7 million in Q4 2023.
  • Average Total Current Liabilities over 5 years is $147.5 million, with a median of $137.9 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities skyrocketed 446.07% in 2021, then crashed 47.77% in 2023.
  • Year by year, Total Current Liabilities stood at $137.0 million in 2021, then decreased by 10.96% to $122.0 million in 2022, then tumbled by 47.77% to $63.7 million in 2023, then surged by 47.13% to $93.8 million in 2024, then skyrocketed by 270.56% to $347.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for ARWR at $347.4 million in Q4 2025, $195.5 million in Q3 2025, and $194.5 million in Q2 2025.